Evidence map›Paper›PMID 37583967›Full record

ArticleERJ open research2023

Serial lung ultrasound in monitoring viral pneumonia: the lesson learned from COVID-19.

David Clofent, Mario Culebras, Almudena Felipe-Montiel, Marta Arjona-Peris, Galo Granados, María Sáez, Florencia Pilia, Antía Ferreiro, Antonio Álvarez, Karina Loor and 2 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

David ClofentDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID https://orcid.org/0000-0002-5769-4993
Mario CulebrasDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Almudena Felipe-MontielDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Marta Arjona-PerisDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4997-483X
Galo GranadosDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID https://orcid.org/0000-0002-1902-1835
María SáezDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Florencia PiliaDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Antía FerreiroDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID https://orcid.org/0000-0001-5679-8830
Antonio ÁlvarezDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Karina LoorDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Pau Bosch-NicolauVall d'Hebron Institut de Recerca, Barcelona, Spain.ORCID https://orcid.org/0000-0002-7435-1829
Eva PolverinoDepartment of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
Vall d'Hebron Institut de Recerca · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung ultrasound (LUS) has proven to be useful in the evaluation of lung involvement in COVID-19. However, its effectiveness for predicting the risk of severe disease is still up for debate. The aim of the study was to establish the prognostic accuracy of serial LUS examinations in the prediction of clinical deterioration in hospitalised patients with COVID-19. Methods: Prospective single-centre cohort study of patients hospitalised for COVID-19. The study protocol consisted of a LUS examination within 24 h from admission and a follow-up examination on day 3 of hospitalisation. Lung involvement was evaluated by a 14-area LUS score. The primary end-point was the ability of LUS to predict clinical deterioration defined as need for intensive respiratory support with high-flow oxygen or invasive mechanical ventilation. Results: 200 patients were included and 35 (17.5%) of them reached the primary end-point and were transferred to the intensive care unit (ICU). The LUS score at admission had been significantly higher in the ICU group than in the non-ICU group (22 (interquartile range (IQR) 20-26) Conclusion: Serial LUS is a reliable tool in predicting the risk of respiratory deterioration in patients hospitalised due to COVID-19 pneumonia. LUS could be further implemented in the future for risk stratification of viral pneumonia.

Identifiers

PMID37583967
PMCPMC10423983
OpenAlexW4378212596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.